Showing 4411-4420 of 8827 results for "".
- New Biomarkers May Help Advance Melanoma Detectionhttps://practicaldermatology.com/news/new-biomarkers-may-help-advance-melanoma-detection/2461539/New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers at the University of South Australia. “Melanomas exhibit a wide range of sizes, shapes and growth, which can resemble numerous benign and other malignant skin lesions,&
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st
- Daniel Hopkins Named New CEO at AlumierMDhttps://practicaldermatology.com/news/daniel-hopkins-named-new-ceo-at-alumiermd/2461537/Daniel Hopkins is AlumierMD’s new Chief Executive Officer. With more than a decade of experience in the aesthetic sector, Mr. Hopkins is prepared to take AlumierMD's commitment to the global aesthetic community through its next exciting phase of growth. Mr. Hopkins
- Sirnaomics Accelerates Clinical Development of STP705 for isSCC, BCChttps://practicaldermatology.com/news/sirnaomics-accelerates-clinical-development-of-stp705-for-isscc-bcc/2461535/Sirnaomics Ltd. is advancing the clinical development of STP705 for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Based on positive clinical readouts from a Phase IIb study for isSCC and a Phase II study for BCC, Sirnaomics is formul
- Merz Aesthetics, NWSL’s North Carolina Courage Expand Partnershiphttps://practicaldermatology.com/news/merz-aesthetics-partners-with-wsls-north-carolina-courage-to-fuel-confidence-on-and-off-field/2461532/Merz Aesthetics is expanding its sponsorship of the North Carolina Courage, two-time champions of the National Women’s Soccer League (NWSL). “This partnership is so meaningful for us at Merz Aesthetics,” says Patrick Urban, North America President, in
- Spotlight on: Lanolin Allergenicityhttps://practicaldermatology.com/news/spotlight-on-lanolin-allergenicity/2461531/The phenomenon of lanolin allergenicity is the focus of the Contact Allergen of the Year article in <
- CDC Report: Seven Percent of Adults and 11 Percent of Kids Had Eczema in 2021https://practicaldermatology.com/news/cdc-report-seven-percent-of-adults-and-11-percent-of-kids-had-eczema-in-2021/2461530/Slightly more than 7% of adults and nearly 11% of kids had eczema in 2021, according to two new reports in the CDC’s National Center for Health Statistics Data Brief. W
- Study: 3D-printed Artificial Skin Can Be Used in Cosmetics and Drug Testinghttps://practicaldermatology.com/news/study-3d-printed-artificial-skin-can-be-used-in-cosmetics-and-drug-testing/2461525/Bioprinted artificial skin can be used in cosmetics and drug testing, a new study shows. For the study, researchers compared the conventional mimetic model based on manual pipetting with extrusion bioprinting, which “allows the in vitro reconstruction of a more relevant and repres
- Mount Sinai Researchers Awarded $12 Million NIH Grant to Create a Center to Study Causes of Atopic Dermatitis and Food Allergyhttps://practicaldermatology.com/news/mount-sinai-researchers-awarded-12-million-nih-grant-to-create-a-center-to-study-causes-of-atopic-dermatitis-and-food-allergy/2461520/Mount Sinai researchers have been awarded $12 million over 5 years by the National Institutes of Health (NIH) to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis, according to a news release. The Systems Biology of Early Ato
- Sun Pharma to Acquire Concert Pharmaceuticals, Maker of Alopecia Areata Treatment Candidatehttps://practicaldermatology.com/news/sun-pharma-to-acquire-concert-pharmaceuticals-maker-of-alopecia-areata-treatment-candidate/2461519/Sun Pharmaceutical Industries announced it has acquired Concert Pharmaceuticals for about $576 million in equity value, according to a company news release. Concert’s lead product candidate is deuruxolitinib, an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of alopecia a